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Abstract We report the risks of a comprehensive range of
disease and drug categories on hip fracture occurrence
using a strict population-based cohort design. Participants
included the source population of a Swedish county, aged
C50 years (n = 117,494) including all incident hip frac-
tures during 1 year (n = 477). The outcome was hospi-
talization for hip fracture (ICD-10 codes S72.0–S72.2)
during 1 year (2009–2010). Exposures included: preva-
lence of (1) inpatient diseases [International Classification
of Diseases (ICD) codes A00–T98 in the National Patient
Register 1987–2010] and (2) prescribed drugs dispensed in
2010 or the year prior to fracture. We present age- and sex-
standardized risk ratios (RRs), risk differences (RDs) and
population attributable risks (PARs) of disease and drug
categories in relation to hip fracture risk. All disease cat-
egories were associated with increased risk of hip fracture.
Largest risk ratios and differences were for mental and
behavioral disorders, diseases of the blood and previous
fracture (RRs between 2.44 and 3.00; RDs (per 1000 per-
son-years) between 5.0 and 6.9). For specific drugs,
strongest associations were seen for antiparkinson (RR
2.32 [95 % CI 1.48–1.65]; RD 5.2 [1.1–9.4]) and antide-
pressive drugs (RR 1.90 [1.55–2.32]; RD 3.1 [2.0–4.3]).
Being prescribed C10 drugs during 1 year incurred an
increased risk of hip fracture, whereas prescription of
cardiovascular drugs or B5 drugs did not appear to increase
risk. Diseases inferring the greatest PARs included: car-
diovascular diseases PAR 22 % (95 % CI 14–29) and
previous injuries (PAR 21 % [95 % CI 16–25]; for specific
drugs, antidepressants posed the greatest risk (PAR 16 %
[95 % CI 12.0–19.3]).
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Introduction
Hip fracture is a major cause of disability, dependency and
excess mortality among older populations [1, 2], and
identification of those at highest risk is of increasing rele-
vance in light of the aging population structure. The vast
majority of hip fractures are caused by falls among older
people [3, 4], and those with a high prevalence of coex-
isting disease are more predisposed to falls and hip fracture
[5–7]. Hip fracture incidence rises 44-fold in women
between age 55 and 85, and the impact by increasing age is
11-fold greater than that associated with the age-related
decline in BMD [3]. Preexisting disease, increasing in
prevalence with increasing age, may increase hip fracture
risk by predisposing to falls or reducing bone strength, or
Electronic supplementary material The online version of this
article (doi:10.1007/s00223-016-0194-7) contains supplementary
material, which is available to authorized users.
& Breiffni Leavy
breiffni.leavy@ki.se
1 Division of Physiotherapy, Department of Neurobiology,
Care Sciences and Society, Karolinska Institute, Huddinge,
Sweden
2 Stockholms Sjukhem Foundation, Stockholm, Sweden
3 Department of Surgical Sciences, Orthopedics, Uppsala
University, Uppsala, Sweden
4 Department of Public Health and Caring Sciences, Geriatrics,
Uppsala University, Uppsala, Sweden
5 School of Education, Health and Social Studies, Dalarna
University, Falun, Sweden
6 Department of Medical Sciences, Osteoporosis and Clinical
Pharmacogenetics, Uppsala University, Uppsala, Sweden
123
Calcif Tissue Int (2017) 100:1–12
DOI 10.1007/s00223-016-0194-7
both. In addition, many medications are associated with
increased risk of falls and fractures [8, 9], either due to the
intended drug effects, or due to unwanted side effects
which commonly occur in elderly populations [10]. Dis-
eases affecting the central nervous system (Parkinson’s
disease [11], stroke [12], dementia and depression [13, 14],
musculoskeletal conditions [15], cardiovascular conditions
[12] and bone mineral density [16]) are all implicated in
falls and hip fracture occurrence. Drugs affecting the
central nervous system, such as sedatives, antidepressants
and anticonvulsants, are thought to predispose to falls by
slowing cognitive or reflex reaction alertness [8, 17]. These
drugs, along with certain cardiovascular drugs, are com-
monly categorized as fall-risk-increasing drugs [18]. Car-
diovascular medications are commonly associated with
increased risk of falls and hip fracture due to their
propensity to cause or worsen orthostatic hypotension in
older people, although evidence for the strength of these
associations is differing [9, 19, 20].
There is a scarcity of population-based studies reporting
the relative or absolute risks of disease and drugs on hip
fracture, and such knowledge would provide important
information on the public health impact of diseases and
their pharmaceutical treatments on hip fracture occurrence
[14, 21]. Cohort studies with recruitment based on clinical
examination will fail to identify important disease risk
factors due to non-inclusion of the frailest elderly. In
addition, self-reported diseases at baseline will be under-
estimated compared with complete register information
[12]. Additionally, by focusing on younger [6] or com-
munity-dwelling populations only [22], previous studies
have not accounted for the oldest old with highest disease
burden. This will in turn produce risk estimates not
applicable to residential care dwellers, a group who are at
highest risk of falls and account for one-third of all patients
with hip fracture [23]. The aim of this study is therefore to
report the risks posed by disease and dispensed drugs
identified from register data for the incidence of hip frac-
ture, using a strict population-based cohort design.
Methods
Subjects and Outcome
All men and women aged 50 years and older (born 1960
and earlier) residing in Uppsala County, Sweden, in 2010
were considered as source population (n = 117,494). All
incident and radiographically confirmed hip fractures
[S72.0–S72.2 according to the International Classification
of Diseases 10th revision (ICD-10)] occurring in Uppsala
County and admitted to Uppsala University Hospital
between June 8, 2009, and June 8, 2010 (n = 477), were
identified and individually validated by cross-checking of
medical records [23]. Pathological (n = 5), periprosthetic
(n = 12) and those fractures where surgical treatment did
not occur at Uppsala University Hospital (n = 15) were
excluded.
The study was approved by the Regional Ethical Review
Board in Uppsala. Data concerning the structure of the
source population were retrieved from Statistics Sweden’s
database (online), available at: www.statistikdatabasen.scb.
se/pxweb/sv/ssd/, accessed October 9, 2015.
Exposures
The National Board of Health and Welfare provided
anonymized information on diseases and drugs in sex and
age-specific strata (age categories: 50–54, 55–59, 60–64,
65–69, 70–74, 75–79, 80–84, 85?) both for the source
population and for those with hip fracture.
Diseases
Information on diseases was collected from the national
patient registry for in-patient care, a nationwide register of
all in-patient care in Sweden since 1987. The National
Board of Health and Welfare does not hold the register of
the total population. The number of persons with record of
diseases in the source population was therefore approxi-
mated by all records of in-patient care occurring in Upp-
sala County during the period January 1, 1987–January 1,
2010, among those persons alive on January 1, 2010. For
subjects with a hip fracture outcome, information was
collected between January 1, 1987, and the day before hip
fracture. Information on diagnoses according to ICD-10
chapters was collected: infectious and parasitic diseases
(A00–B99); malignant tumors (C00–C97); non-malignant
tumors (D00–D48); diseases of blood/blood-forming
organs (D50–D89); endocrine, nutritional and metabolic
disorders (E00–E90); mental and behavioral disorders
(F00–F99); diseases of the nervous system (G00–G99);
eye (H00–H59); ear (H60–H95); circulatory system (I00–
I99); respiratory system (J00–J99); digestive system (K00–
K93); skin and subcutaneous tissue (L00–L99); muscu-
loskeletal system (M00–M99); genitourinary system (N00–
N99); previous injury (S00–T98); and fracture injury (S12/
S22/S32/42/52/62/72/82), which was a subcategory of
injury. Data were extracted such that each diagnosis could
be counted once per individual. For subjects with two hip
fractures during the observation period (n = 7), the date of
the second fracture was used as the index date, to prevent
diseases being diagnosed more than once for the same
individual.
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Drugs
The number of persons being prescribed certain drugs was
extracted from the Swedish prescribed drug register. For
the source population, this was approximated by all dis-
pensed prescribed drugs registered in Uppsala County
during 2010. For subjects with incident hip fracture, all
drugs dispensed during 1 year before date of hip fracture
were counted. We considered the following drugs or
combination of drugs and their ATC (anatomic therapeutic
chemical classification system) codes: drugs used in dia-
betes (A10), systemic corticosteroids (H02), antiparkinson
drugs (N04), antidepressives (N06A), benzodiazepines
(N05BA); opioid, anxiolytic, hypnotics and sedatives drugs
(‘sedatives’; one or more of N02A, N05B-C); cardiovas-
cular system drugs (C); nervous system drugs (N); and fall-
risk-increasing drugs defined according to the Swedish
National Board of Health and Welfare guidelines [18]
which included both psychotropic and cardiovascular drugs
(C1 of N02A, N03A, N04A-B, N05A-C, N06A and C1 of
C01A, C01BA, C01D, C02, C03, C07–C09, G04CA). The
total number of drugs dispensed during 1 year was also
assessed and presented as C5 drugs/year and C10 drugs/
year.
Statistical Analysis
A cohort analysis was performed using the source popu-
lation as the underlying subjects at risk with the 477 inci-
dent hip fractures as outcome. Prevalence of each disease
and drug category was calculated stratified by hip fracture
outcome. Using risk among those unexposed for each
disease or drug category as reference, we calculated risk
ratios (RR) and risk differences (RD; risk in the exposed
minus the risk in the unexposed, per 1000 person-years)
with corresponding 95 % confidence intervals stratified by
age (in 5-year strata) and sex and directly standardized to
the age and sex distribution of the total population in
Uppsala County in 2010 using the ‘cs’ command in Stata.
Calculations were additionally done stratified by sex and
by age category (50–69; 70–79; 80? years). The popula-
tion attributable risk (PAR) (given as a % with corre-
sponding 95 % confidence intervals) was calculated as:
prevalence of the exposure among cases multiplied by (1-1/
RR) [24]. Statistical analyses were performed using Stata
13.1 (Stata Corp., Collage Station, TX, USA).
Results
Demographic characteristics of the study population by hip
fracture are outlined in Table 1. Women and people
80 years and older were overrepresented among those with
hip fracture. Among those aged C65 years with hip frac-
ture, 32 % were living in residential care compared to
approximately 5 % [25] of those of similar age living in
residential care in the region. The 1-year absolute risk of
hip fracture in the population aged C50 years was 4.1/1000
person-years.
Prevalence of each disease and drug category by hip
fracture status and by age group is outlined in Table 2. The
most prevalent disease category included circulatory sys-
tem diseases and previous injury; 59 % of those with hip
fracture and 25 % of the remaining population had preva-
lent circulatory system disease. Corresponding prevalence
for previous injury was 43 and 17 %. Drugs in the car-
diovascular and nervous system categories were most
commonly prescribed. Of note is that 56 % of hip fracture
cases had been prescribed sedatives and 52 % prescribed
fall-risk-increasing drugs. Prevalence of both diseases and
prescribed drugs increased with age.
No major differences were observed across disease
exposures between men and women, and a combined
estimate is therefore presented although estimates stratified
by sex are given in Supplementary Table 1.
To estimate the association between each disease cate-
gory and hip fracture risk, age- and sex-standardized risk
ratios (RR) and differences (RD) were calculated (Fig. 1a).
All disease categories were associated with an increased
risk of hip fracture, and highest RRs were observed for
mental and behavioral disorders (RR 3.00, 95 % CI
2.40–3.76), diseases of the blood (RR 2.70, 95 % CI
1.99–3.65) and previous fractures (RR 2.44, 95 % CI
1.96–3.04). An approximately twofold increase in risk was
seen for previous injuries and disorders of the nervous
system (Fig. 1a). An approximate 1.6-fold increase in risk
was observed for more prevalent conditions such as cir-
culatory system disorders (RR 1.61, 95 % CI 1.32–1.95)
and endocrine disorders (RR 1.63, 95 % CI 1.33–1.99).
Conditions with largest risk differences for hip fracture
occurrence (per 1000 person-years) included mental and
behavioral disorders (6.9), diseases of the blood (6.4),
previous fractures (5.0) and diseases of the nervous system
(4.0). In relation to age, RRs for all disease categories were
highest among the youngest age groups (50–69 years) and
decreased with increasing age although risk differences
were lower. For example, having a mental and behavioral
disorder was associated with a fivefold increase in risk
among those 50–69 years with a risk difference of 3/1000
person-years; for the age group 70–79, the risk was
increased fivefold (risk difference 15/1000 person-years),
and for the oldest age group (80?), there was a twofold
increased risk with a risk difference of 17/1000 person-
years (Table 3).
For drugs dispensed over 1 year (Fig. 1b), the largest
RRs and RDs (per 1000 person-years) were observed for
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antiparkinson drugs (RR 2.32, 95 % CI 1.48–3.65; RD 5.2,
95 % CI 1.1–9.4) and antidepressive drugs (RR 1.90, 95 %
CI 1.55–2.32; RD 3.1, 95 % CI 2.0–4.3), whereas diabetes
drugs incurred no increased risk (RR 0.99, 95 % CI
0.75–1.32). Benzodiazepines (RR 1.46, 95 % CI
1.14–1.87) and other sedative drugs (RR 1.39, 95 % CI
1.15–1.68) were also associated with an increased risk of
hip fracture. Being prescribed fall-risk-increasing drugs (a
combination of cardiovascular and nervous system drugs)
was associated with 47 % increased risk of hip fracture
(RR 1.47, 95 % CI 1.21–1.78). However, the overall esti-
mate for cardiovascular drugs on hip fracture was 0.52
(95 % CI 0.41–0.67). The age-stratified analysis revealed
that this is driven by the RR in the highest age group with
RRs of 1.34 (0.81–2.21) and 1.38 (0.90–2.12) for age
groups B69 and 70–79 years, respectively (Table 3). A
similar pattern was seen for being prescribed 5 or more
drugs during 1 year; the RR for hip fracture was 2.83
(1.65–4.84) for those aged B69 years (Fig. 1b; Table 3).
Being prescribed 10 or more drugs during 1 year was
associated with an increased risk of hip fracture (Fig. 1b,
Table 3). The age-related decline in relative risk for drugs
was not as established a pattern as that for diseases,
although RRs were lower in general in the oldest age cat-
egory (C80 years) than in the youngest (B69 years).
In order to establish the proportion in the overall pop-
ulation attributable to disease or drug exposures, we cal-
culated the PAR. For disease exposures, highest PARs
occurred for cardiovascular diseases (22.4 %, 95 % CI
14.4–29.0), injuries (21.0 %, 95 % CI 16.4–24.7), previous
fracture (18.3 %, 95 % CI 15.2–20.8) and mental and
behavioral disorders (16.5 %, 95 % CI 14.4–18.2). PAR
for diseases of the blood was 10.6 % (95 % CI 8.4–12.2).
Specific drugs incurring the highest attributable risks at the
population level were antidepressives (PAR 16.1 %, 95 %
CI 12.1–19.3) and sedative drugs (PAR 15.6 %, 95 % CI
7.1–22.6), in addition to fall-risk-increasing drugs (PAR
16.7 %, 95 % CI 9.0–23.0) and more than 10 drugs dis-
pensed during 1 year (PAR 16.4 %, 95 % CI 8.8–22.7).
Given a low prevalence, PAR for antiparkinson drugs was
only 3.1 % (95 % CI 1.8–4.0).
Discussion
We assessed the relative and absolute risk of hip fracture
during 1 year based on the entire population of a Swedish
County in relation to a wide range of disease and drug
categories. Hospitalization for any disease posed an
increased risk of future hip fracture, with largest risk
estimates seen for mental and behavioral disorders, dis-
eases of the blood and previous fracture. Prescriptions of
antiparkinson or antidepressive drugs were associated with
largest increased risk of hip fracture.
The main strengths of the study include the capturing
and subsequent verification of all incident hip fractures
during 1 year in a Swedish county. The patient register
covers all in-patient care in Sweden since 1987, and as
reporting is mandatory, disease recording is of high quality
[26]. The prescribed drug register includes information on
all prescription medicines dispensed at Swedish pharma-
cies, hospitals and residential care facilities. Both registers
allow individual matching using the personal identification
number from all Swedish residents. Information on dis-
eases and dispensed drugs was collected for the source
population and those with hip fracture during the 1-year
study period, allowing for a true population-based cohort
analysis. Data were provided by the National Board of
Health and Welfare in sex and age strata. However, since
the National Board of Health and Welfare does not hold the
Table 1 Characteristics of the
study population (n = 117 494)
Characteristic, n (%) No hip fracture, n = 117 017 Hip fracture, n = 477
Sex
Men 56 084 (47.9) 144 (30.2)
Women 60 933 (52.1) 333 (69.8)
Age, years (%)
50–69 80 727 (69.0) 64 (13.4)
70–79 21 502 (18.4) 115 (24.1)
C80 14,788 (12.6) 298 (62.4)
Residencea
Community (living alone), n (%) Na 144 (30.3)
Community (living with other), n (%) Na 183 (38.4)
Residential care facility, n (%) Nab 149 (31.3)
a Missing information in one person with hip fracture
b Figures available for population in Uppsala County aged C65 years 2010: 2628 (4.7 %) [25]
4 B. Leavy et al.: The Impact of Disease and Drugs on Hip Fracture Risk
123
Table 2 Prevalence of diseases and prescribed drugs





















8052 (6.9) 87 (18.2) 3798 (4.7) 9 (14.1) 1764 (8.2) 12 (10.4) 2490 (16.8) 66 (22.1)
Malignant neoplasms (C) 8452 (7.2) 66 (13.8) 3845 (4.8) 11 (17.2) 2451 (11.4) 19 (16.5) 2156 (14.6) 36 (12.1)
Non-malignant neoplasms
(D00-D48)
5674 (4.8) 43 (9.0) 3481 (4.3) 7 (10.9) 1129 (5.3) 11 (9.6) 1064 (7.2) 25 (8.4)
Diseases of the blood/blood-
forming organs (D50–89)
4265 (3.6) 80 (16.8) 1631 (2.0) 10 (15.6) 896 (4.2) 15 (13.0) 1738 (11.8) 55 (18.5)
Endocrine, nutritional and
metabolic disorders (E)
14,602 (12.5) 148 (31.0) 6839 (8.5) 16 (25.0) 3886 (18.1) 39 (33.9) 3877 (26.2) 93 (31.2)
Mental and behavioral
disorders (F)
7971 (6.8) 118 (24.7) 4812 (6.0) 15 (23.4) 1283 (6.0) 26 (22.6) 1876 (12.7) 77 (25.8)
Diseases of the nervous
system (G)
7250 (6.2) 90 (18.9) 3532 (4.4) 13 (20.3) 1767 (8.2) 21 (18.3) 1951 (13.2) 56 (18.8)
Diseases of the eye and
adnexa (H00-H59)
3883 (3.3) 52 (10.9) 1523 (1.9) 3 (4.7) 944 (4.4) 11 (9.6) 1416 (9.6) 38 (12.8)
Diseases of the ear and
mastoid process (H60-H95)
2754 (2.4) 23 (4.8) 1441 (1.8) 2 (3.1) 611 (2.8) 5 (4.3) 702 (4.7) 16 (5.4)
Diseases of the circulatory
system (I)
29,018 (24.8) 283 (59.3) 12,690 (15.7) 20 (31.3) 7730 (36.0) 66 (57.4) 8598 (58.1) 197 (66.1)
Diseases of the respiratory
system (J)
10,682 (9.1) 117 (24.5) 5198 (6.4) 14 (21.9) 2485 (11.6) 19 (16.5) 2999 (20.3) 84 (28.2)
Diseases of the digestive
system (K)
18,450 (15.8) 144 (30.2) 10,726 (13.3) 12 (18.8) 3860 (18.0) 31 (27.0) 3864 (26.1) 101 (33.9)
Diseases of the skin and
subcutaneous tissue (L)




17,953 (15.3) 151 (31.7) 9181 (11.4) 12 (18.8) 4234 (19.7) 32 (27.8) 4538 (30.7) 107 (35.9)
Diseases of the genitourinary
system (N)
15,853 (13.5) 154 (32.3) 8037 (10.0) 12 (18.8) 3415 (15.9) 32 (27.8) 4401 (29.8) 110 (36.9)
Injury, poisoning and certain
other consequences of
external causes (S–T)
19,399 (16.6) 203 (42.6) 10,559 (13.1) 25 (39.1) 4010 (18.6) 42 (36.5) 4830 (32.7) 136 (45.6)
Fracture of the neck, thorax,
spine, arm, hip, leg, ankle
(S12/S22/S32/42/52/62/72/
82)
9722 (8.3) 148 (31.0) 4576 (5.7) 20 (31.3) 2007 (9.3) 30 (26.1) 3139 (21.2) 98 (32.9)
Drug (ATC code)
Drugs used in diabetes (A10) 10,686 (9.1) 57 (11.9) 5714 (7.1) 6 (9.4) 2964 (13.8) 21 (18.3) 2008 (13.6) 30 (10.1)
Corticosteroids systemic
(H02)
7984 (6.8) 41 (8.6) 4542 (5.6) 8 (12.5) 1922 (8.9) 13 (11.3) 1520 (10.3) 20 (6.7)
Antiparkinson drugs (N04) 2027 (1.7) 26 (5.5) 879 (1.1) 4 (6.3) 563 (2.6) 11 (9.6) 585 (4.0) 11 (3.7)
Benzodiazepines (N05BA) 9018 (7.7) 103 (21.6) 4178 (5.2) 7 (10.9) 2004 (9.3) 19 (16.5) 2836 (19.2) 77 (25.8)
Opioid, anxiolytic, hypnotics
and sedatives drugsa
33,119 (28.3) 267 (56.0) 18,048 (22.4) 25 (39.1) 7115 (33.1) 61 (53.0) 7956 (53.8) 181 (60.7)
Antidepressant drugs (N06A) 16,006 (13.7) 162 (34.0) 9332 (11.6) 14 (21.9) 2909 (13.5) 35 (30.4) 3765 (25.5) 113 (37.9)
Cardiovascular system drugs
(C)
59,165 (50.6) 362 (75.9) 31,529 (39.1) 35 (54.7) 14,670 (68.2) 87 (75.7) 12,966 (87.7) 240 (80.5)
Nervous system drugs (N) 48,342 (41.3) 356 (74.6) 27,216 (33.7) 38 (59.4) 10,207 (47.5) 80 (69.6) 10,919 (73.8) 238 (79.9)
Fall-risk-increasing drugsb 23,990 (20.5) 250 (52.4) 10,338 (12.8) 19 (29.7) 6081 (28.3) 55 (47.8) 7571 (51.2) 176 (59.1)
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population register, exposures in the source population
were approximated by counting all in-patient treated dis-
eases in Uppsala County occurring between 1987 and 2010
among those still alive January 1, 2010, and by counting all
drugs dispensed in Uppsala County during 2010 in an open
cohort design. This provides a fair approximation of the
total population if it is assumed that inflow and outflow of
inhabitants are equal. However, it also is a potential source
for overestimation of the prevalence of disease in the
source population, especially in the oldest ages, which
would lead to a conservative bias of our estimates. The
disease exposures will not account for all diagnoses made
in outpatient settings which may lead to a conservative bias
toward the null of the prevalence of conditions commonly
treated in out-patient settings, such as diabetes, dementia,
depression or hypertension [26]. This would nonetheless
have been the case for both hip fracture patients and the
total population. In contrast, osteoporosis would have been
more commonly diagnosed in the in-patient register only
among those with history of a previous fall-related fracture.
Using age- and sex-standardized risk ratios for exposures
on a population level, we were not able to estimate the
effects independent of potential covariates such as body
mass index, bone mineral density, smoking or demographic
factors. Neither could we examine the effects of disease
onset or severity or length of treatment with certain drugs.
Furthermore, we cannot tell whether individuals had a
combination of diseases or, in the case of fall-related drugs
and 5 or 10 drugs prescribed during 1 year, whether the
prescribed drugs were taken simultaneously or not. Addi-
tionally, a dispensed drug does not necessarily mean that
the drug was taken.
We observed positive associations between all disease
categories and hip fracture, a pattern reported by others,
albeit for a smaller range of diseases, in relation to falls
[11] and hip fracture [21]. The threefold increased risk of
hip fracture associated with mental and behavioral disor-
ders, the most prevalent of which are disorders caused by
psychoactive substances, mood disorders, schizophrenia
and dementia, is in accordance with the twofold to three-
fold increased risk observed in previous cohort studies
[14, 21]. Dementia and hip fracture share several predis-
posing and intermediate risk factors, such as advanced age,
gait impairments and increased risk of falls [27]. We also
observed an increased risk of hip fracture for hypnotics and
sedative drugs, commonly prescribed to people with
dementia, which are previously reported to adversely affect
postural stability and judgment and further predispose to
injurious falls [17], particularly during nighttime hours
[23]. Our findings involving a doubled risk of hip fracture
associated with antidepressant drugs correspond to results
from previous studies [17, 28]. Others report that antide-
pressants are the most frequently dispensed fall-related
drugs among elderly people in primary care and in insti-
tutional settings [29]. Additionally, the population
attributable risk of 16 % that these medications infer is an
important reminder of the need for restrictive prescription
of antidepressants among elderly people at risk of falls.
Antiparkinson drugs incurred the greatest relative and
absolute risks of hip fracture of all drugs investigated,
despite a low prevalence in the population, as also indi-
cated by the population attributable risk of 3 %.
Dopaminergic medications effectively treat motor impair-
ments and gait performance in Parkinson’s disease [30].
They are, however, also reported to negatively affect pos-
tural adjustments [31] and sway, both factors that could
predispose to fall-related hip fractures. We cannot separate
from our results the effects of disease from drug treatment
of disease, and the observed reductions in RR estimates for
antiparkinson drugs with increasing age (Table 3) may
Table 2 continued

















No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Five or more dispensed drugs
during 1 yearc
57,005 (48.7) 394 (82.6) 29,877 (37.0) 44 (68.8) 13,933 (64.8) 90 (78.3) 13,195 (89.2) 260 (87.2)
Ten or more dispensed drugs
during 1 yearc
25,030 (21.4) 249 (52.2) 10,698 (13.3) 25 (39.1) 6684 (31.1) 56 (48.7) 7648 (51.7) 168 (56.4)
Prevalence of diseases in the in-patient register between 1987 and 2010 for the total population (approximated by all in-patient care registered in
Uppsala County for patients alive January 1, 2010) and between 1987 and day before date of fracture for subjects with hip fracture. Prevalence of
prescribed drugs from the prescribed drug register in 2010 for the total population (approximated by all prescribed drugs registered in Uppsala
County for patients alive January 1, 2010) and for 1 year before date of fracture for subjects with hip fracture
a One or more of N02A, N05B-C
b One or more of N02A, N03A, N04A-B, N05A-C, N06A AND one or more of C01A, C01BA, C01D, C02, C03, C07-C09, G04CA
c Any ATC code
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therefore reflect either reduced exposure to falls due to
reduced mobility, or reduced effectiveness of dopaminergic
agents, both factors that occur in the advanced disease
stages [32].
Previous fracture is a known risk factor for future hip
fracture [33]. We report a RR of 2.44 (95 % CI 1.96–3.04)
for previous fractures which is slightly higher than that
reported in a meta-analysis of 11 cohort studies (RR 1.86,
95 % CI 1.75–1.98) [34]. Our method of registering only
previous fractures which required hospitalization leads to a
channeling toward more severe fractures, which more
strongly predict future hip fracture than minor fractures
cared for in out-patient settings or captured through self-
reported methods. In consideration that the vast majority of
injury-related hospital admissions among elderly people
are fall related [3] and those who fall frequently are at
greatest risk of facture outcomes, hip fracture prevention
may begin by posing simple screening questions relating to
whether an older person has fallen in the previous year or
has an impaired balance [35].
We observed that diseases of the blood inferred an
approximate threefold increased risk of hip fracture, with a
population attributable risk of 10 %. A slightly lower risk
estimate for the effect of pernicious anemia (vitamin B12
deficiency) on hip fracture has been reported previously
[36, 37]. Although vitamin B12 deficiency might negatively
influence bone strength [38], it may not be the sole mech-
anism. Deficiency anemias are common in hip fracture
patients [39]. Anemia in general is most prevalent among
institutionalized elderly people and in the oldest old, and has
been associated with reduced physical performance and falls
[40, 41]. Among the current hip fracture cohort, we were
able to ascertain that 469 out of 477 hip fractures (98 %)
were preceded by a fall. Thus, only in eight patients, specific
fall circumstances were not possible to identify [23]. In
addition, anemia may increase the severity of other
Infectious and parasitic diseases (A−B)
Malignant tumors (C)
Non−malignant tumors (D00−48)
Diseases of blood/blood forming organs (D50−89)
Endocrine, nutritional and metabolic disorders (E)
Mental and behavioural disorders (F)
Nervous system diseases (G)
Diseases of the eye (H00−59)
Diseases of the ear (H60−95)
Circulatory system diseases (I)
Diseases of the respiratory system (J)
Diseases of the digestive system (K)
Diseases of the skin and subcutaneous tissue (L)
Diseases of the musculoskeletal system/connective tissue (M)
Diseases of the genitourinary system (N)
Injuries (S−T)
Fractures (S12/22/32/42/52/62/72/82)
0 1 2 3 4
Risk ratio (95% CI)
−10 −5 0 5 10
Risk difference per 1000 (95% CI)
Diabetes drugs (A10)
Corticosteroids for systemic use (H02)
Drugs for Parkinson’s disease (N04)
Opioids, anxiolytics, hypnotics and sedatives (N02A, N05B−C)
Antidepressive drugs (N06A)
Cardiovascular system drugs (C)
Nervous system drugs (N)
Fall−risk increasing drugs
≥5 dispensed drugs during one year
≥10 dispensed drugs during one year
0 1 2 3 4
Risk ratio (95% CI)
−10 −5 0 5 10
Risk difference per 1000 (95% CI)
A
B
Fig. 1 Standardized risk ratios and risk differences (per 1000) and their 95 % confidence intervals for the association of prevalent in-patient
treated disease between 1987 and 2010 (a) and of dispensed drugs in 2010 (b) with incident hip fracture
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preexisting diseases [40] or influence risk of hip fracture via
other, yet unknown mechanisms. Our results highlight the
importance of investigating the presence of diseases of the
blood, conditions that are often treatable, among at-risk
groups as a part of fracture prevention.
Surprisingly, cardiovascular drugs and having been dis-
pensed five drugs or more during 1 year, were associated
with lower risk of hip fracture. The finding that cardiovas-
cular drugs were associated with reduced risk of hip fracture
appears somewhat contradictory due to their reported
hypotensive effects among older people, a symptom that
commonly precedes hip fracture in the clinical context [42].
Nonetheless, there are previous studies reporting weak
associations between cardiovascular drugs and falls [9] and
hip fractures [43, 44]. It is also possible that the apparent
protective effect of cardiovascular drugs occurs due to our
strict population-based cohort, which includes residential
care dwellers with the poorest health, who are reported less
likely to receive cardiovascular drugs when compared with
community dwellers [45]. These differences in prescription
are proposed to be due to a lack of adherence to treatment
guidelines, as opposed to lower cardiovascular disease
prevalence in this group [46]. Indeed, the inverse associa-
tion in our study seems to be driven by the inverse associ-
ation in the oldest age category, whereas in younger ages
prescribed cardiovascular drugs are associated with
increased risk of hip fracture. Nevertheless, we report that
circulatory system diseases were associated with a doubled
risk of hip fracture, which falls within the wide range of
estimates reported for stroke and heart failure, estimates that
vary in relation to age, sex and time since disease onset in
previous studies [12, 47]. Furthermore, cardiovascular dis-
ease posed the largest population attributable risk (22 %).
Interestingly, we observed that being prescribed five or
more medications during 1 year did not infer an increased
overall risk of hip fracture, whereas being prescribed ten or
more medications during 1 year did. However, as with
cardiovascular drugs, this inverse association was driven
by the highest age group as an increased risk of hip fracture
was seen for those younger than 80 years. One possible
interpretation could be that in our cohort, the use of up to
five drugs is a marker for health-seeking behavior or for
community dwellers with a relatively lower disease bur-
den, since the drug register enabled us to establish the
number of dispensed medications during 1 year, but not the
extent to which these drugs were taken simultaneously.
The concomitant use of more than five drugs, on the other
hand, has been shown to be twice as common among
institutionalized elderly in Sweden, a group with frailer
health status [45]. Additionally, those receiving a greater
number of drugs are also more likely to receive psy-
chotropic fall-risk-increasing drugs [48, 49] which could
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in our findings. The literature regarding the effects of
polypharmacy on hip fracture is conflicting, possibly
reflecting the complex underlying mechanisms affecting
the relationship between polypharmacy and fracture risk
which include: confounding effects of disease, nature of the
drugs, and/or interaction effects between specific drugs. A
recent nested case–control study reported higher odds
ratios for hip fracture when taking two or more drugs [50].
This is in contrast to positive relationships between
polypharmacy and injurious falls reported in a cohort
study, when only in the presence of established fall-related
drugs [51].
In a population-based setting of adults aged 50 and
older, the 1-year risk of hip fracture is higher among those
that previously were hospitalized for any disease but
especially so for mental and behavioral disorders, diseases
of the blood and previous injury. Additionally, being pre-
scribed antiparkinson, antidepressive, sedative or ten or
more medications during 1 year, all associate with
increased risk of hip fracture. Using a strict population-
based cohort, we were able to report the impact of a wide
range of disease and drug categories on risk of hip fracture.
Our results add to the few existing studies which have
included the frailest members of the elderly population
when calculating the impact of disease and drugs on hip
fracture risk.
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